Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for Prevention of Nausea and Vomiting in Hematologic Malignancies
NCT00954941Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2009
- Primary completion
- Apr 2013
- Countries
- 1
- Sponsor
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Drugs
- aprepitant
- Conditions
- chemotherapy-induced nausea and vomiting (CINV)
01
Overview
Phase 2, randomised, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2009; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients >= 18 years with AML, high-risk MDS, CML in blast crisis, or acute undifferentiated leukemia receiving high-dose cytarabine (>= 1g/m^2/d for >= 3 days).
04
Registry description
The goal of this clinical research study is to compare the effectiveness of receiving a combination of ondansetron and aprepitant to receiving ondansetron alone in helping to prevent nausea and/or vomiting in patients with Acute myeloid leukemia (AML) or high-risk (HR) Myelodysplastic syndromes (MDS) who are receiving cytarabine. The safety of this drug combination will also be studied.
Beyond the preview
Go deeper on NCT00954941.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954941.